FOLLOW-UP TO THE 2011 POLITICAL DECLARATION ON HIV/AIDS: INTENSIFYING EFFORTS TO ELIMINATE HIV/AIDS | Reporting Period: January – December 2014
Technical Brief
Damon Barrett, Gonçalo Figueiredo Augusto, Martiani Oktavia, Jeanette Olsson, Mira Schneiders and Kate Welch provided background papers and literature reviews which informed this technical series.
HIV testing
Policy Brief
July 2015
WHO Annual Meeting with Pharmaceutical Companies and Stakeholders
08 March 2016, Geneva
2015-06-03 - Board presentation - v32.pptx
Eurosurveillance
Impact Factor 5.7
June 2015
www.eurosurveillance.org
Featuring a series of articles on HIV and STI epidemiology, prevention and control among MSM in Europe
Disease Control Priorities, 3rdEdition: Volume 4.
Mental, neurological, and substance use disorders are common, highly disabling, and associated with significant premature mortality. The impact of these disorders on the social and economic well-beingof individuals, families, and societies is large..., growing, and underestimated
more
This volume presents the complex patterns of cancer incidence and death around the world and evidence on effective and cost-effective ways to control cancers. The Disease Control Priorities Volume 3 evaluation of cancer will indicate where cancer treatment is ineffective and wasteful, and offer alte...rnative cancer care packages that are cost-effective and suited to low-resource settings.
Disease Control Priorities, Third Edition: Volume 3
more
Djibuti et al. BMC Public Health (2015) 15:427 DOI 10.1186/s12889-015-1760-z
Evaluation report
September 2014
This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of the opportunities for – and threats to – expand...ing access to affordable antiretroviral therapy (ART).
The report is supplemented by 11 drug profiles that contain more detailed information on pricing trends and patent barriers for key antiretroviral drugs and fixed-dose combinations. Also included is an annex of conditions that define eligibility for reduced prices from 15 pharmaceutical companies.
more